Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma

Noboru Ideno, Ohtsuka Takao, Taketo Matsunaga, Hideyo Kimura, Yusuke Watanabe, Koji Tamura, Teppei Aso, Shinichi Aishima, Yoshihiro Miyasaka, Kenoki Ouchida, Junji Ueda, Shunichi Takahata, Yoshinao Oda, Kazuhiro Mizumoto, Masao Tanaka

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN. Methods: The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods.Results: The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25%, vs 61/94, 65%; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43%) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9%) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91%) of 23 patients.Conclusions: Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined.

Original languageEnglish
Pages (from-to)311-320
Number of pages10
JournalPancreas
Volume44
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Mutation
Stomach
Neoplasms
Mutation Rate
Pancreas
Multivariate Analysis
DNA

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. / Ideno, Noboru; Takao, Ohtsuka; Matsunaga, Taketo; Kimura, Hideyo; Watanabe, Yusuke; Tamura, Koji; Aso, Teppei; Aishima, Shinichi; Miyasaka, Yoshihiro; Ouchida, Kenoki; Ueda, Junji; Takahata, Shunichi; Oda, Yoshinao; Mizumoto, Kazuhiro; Tanaka, Masao.

In: Pancreas, Vol. 44, No. 2, 01.01.2015, p. 311-320.

Research output: Contribution to journalArticle

Ideno, N, Takao, O, Matsunaga, T, Kimura, H, Watanabe, Y, Tamura, K, Aso, T, Aishima, S, Miyasaka, Y, Ouchida, K, Ueda, J, Takahata, S, Oda, Y, Mizumoto, K & Tanaka, M 2015, 'Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma', Pancreas, vol. 44, no. 2, pp. 311-320. https://doi.org/10.1097/MPA.0000000000000258
Ideno, Noboru ; Takao, Ohtsuka ; Matsunaga, Taketo ; Kimura, Hideyo ; Watanabe, Yusuke ; Tamura, Koji ; Aso, Teppei ; Aishima, Shinichi ; Miyasaka, Yoshihiro ; Ouchida, Kenoki ; Ueda, Junji ; Takahata, Shunichi ; Oda, Yoshinao ; Mizumoto, Kazuhiro ; Tanaka, Masao. / Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. In: Pancreas. 2015 ; Vol. 44, No. 2. pp. 311-320.
@article{a6cc985af1fd4161951374a9801833e2,
title = "Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma",
abstract = "Objective: The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN. Methods: The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods.Results: The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25{\%}, vs 61/94, 65{\%}; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43{\%}) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9{\%}) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91{\%}) of 23 patients.Conclusions: Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined.",
author = "Noboru Ideno and Ohtsuka Takao and Taketo Matsunaga and Hideyo Kimura and Yusuke Watanabe and Koji Tamura and Teppei Aso and Shinichi Aishima and Yoshihiro Miyasaka and Kenoki Ouchida and Junji Ueda and Shunichi Takahata and Yoshinao Oda and Kazuhiro Mizumoto and Masao Tanaka",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MPA.0000000000000258",
language = "English",
volume = "44",
pages = "311--320",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma

AU - Ideno, Noboru

AU - Takao, Ohtsuka

AU - Matsunaga, Taketo

AU - Kimura, Hideyo

AU - Watanabe, Yusuke

AU - Tamura, Koji

AU - Aso, Teppei

AU - Aishima, Shinichi

AU - Miyasaka, Yoshihiro

AU - Ouchida, Kenoki

AU - Ueda, Junji

AU - Takahata, Shunichi

AU - Oda, Yoshinao

AU - Mizumoto, Kazuhiro

AU - Tanaka, Masao

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN. Methods: The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods.Results: The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25%, vs 61/94, 65%; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43%) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9%) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91%) of 23 patients.Conclusions: Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined.

AB - Objective: The aims of this study were to investigate the GNAS mutational status in pancreatic intraductal papillary mucinous neoplasm (IPMN) with and without distinct pancreatic ductal adenocarcinoma (PDAC) and to evaluate the significance of GNAS analysis using duodenal fluid (DF) in patients with IPMN. Methods: The clinicopathologic features of 110 patients with IPMN including 16 with distinct PDAC were reviewed. The GNAS status in the IPMN tissue and 23 DF specimens was assessed by sensitive mutation scanning methods.Results: The GNAS mutation rate in IPMN with distinct PDAC was significantly lower than that in IPMN without PDAC (4/16, 25%, vs 61/94, 65%; P = 0.0047). By multivariate analysis, GNAS wild-type and gastric type IPMNs were significantly associated with distinct PDAC. Of 45 GNAS wild-type IPMNs, 10 (43%) of 23 gastric type IPMNs had distinct PDAC, whereas only 2 (9%) of 22 non-gastric type IPMNs had distinct PDAC (P = 0.017). The GNAS status in DF was consistent with that in tissue in 21 (91%) of 23 patients.Conclusions: Distinct PDACs frequently develop in the pancreas with gastric type IPMN without GNAS mutations. Duodenal fluid DNA test would predict the GNAS status of IPMN, whereas the detection of the gastric subtype using noninvasive test remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=84925872824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925872824&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000258

DO - 10.1097/MPA.0000000000000258

M3 - Article

C2 - 25479586

AN - SCOPUS:84925872824

VL - 44

SP - 311

EP - 320

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -